Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Berobenatide

Stage Phase 3Stale

Sponsor Pfizer

Route injection

Mechanism Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)

Sources

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT07311850

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Pfizer. Enrollment 3578. Conditions Obesity and Overweight. This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks

ClinicalTrials.gov NCT07311850 protocol and results modules

registry, as of 2026-11-04

https://clinicaltrials.gov/study/NCT07915609

A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2). Overall status RECRUITING. Phases PHASE3. Lead sponsor Pfizer. Enrollment 756. Conditions Obesity; Overweight and/or Obesity; Knee Osteoarthritis; Diabetes Melliuts, Type 2. The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity with and without type 2 diabetes. The study will last 52 weeks and compare the effects of berobe

ClinicalTrials.gov NCT07915609 protocol and results modules

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT07845500

A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor Pfizer. Enrollment 660. Conditions Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity. The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes. Participants will be in the study

ClinicalTrials.gov NCT07845500 protocol and results modules

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT07919678

A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1). Overall status RECRUITING. Phases PHASE3. Lead sponsor Pfizer. Enrollment 656. Conditions Obesity; Overweight; Osteoarthritis of the Knee. The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on kne

ClinicalTrials.gov NCT07919678 protocol and results modules

registry, as of 2026-11-06

https://clinicaltrials.gov/study/NCT07874633

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor Pfizer. Enrollment 432. Conditions Obesity; Overweight. Overweight and obesity are long-term health conditions that can increase the possibility of serious health problems. These problems include heart disease, type 2 diabetes (a condition that causes high blood sugar), and other medical conditions. The purpose of this study is to lea

ClinicalTrials.gov NCT07874633 protocol and results modules

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT07792954

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor Pfizer. Enrollment 300. Conditions Obesity; Overweight. Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions. The purpose of this study is to learn whether berobenatide is safe and effective for adults in Ch

ClinicalTrials.gov NCT07792954 protocol and results modules

registry, as of 2026-11-06

https://clinicaltrials.gov/study/NCT07881757

A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2). Overall status RECRUITING. Phases PHASE3. Lead sponsor Pfizer. Enrollment 258. Conditions Apnea; Sleep Disorders; Overweight and/or Obesity. This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea \[OSA\]) and overweight or obesity who ar

ClinicalTrials.gov NCT07881757 protocol and results modules

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT07823608

A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1). Overall status RECRUITING. Phases PHASE3. Lead sponsor Pfizer. Enrollment 258. Conditions Apnea; Sleep Disorders; Overweight and/or Obesity. This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea \[OSA\]) and overweight or obesity who us

ClinicalTrials.gov NCT07823608 protocol and results modules

registry, as of 2026-11-06

https://clinicaltrials.gov/study/NCT07794774

A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM). Overall status RECRUITING. Phases PHASE3. Lead sponsor Pfizer. Enrollment 197. Conditions Obesity. The purpose of this clinical study is to learn about safety and effects of berobenatide (PF-08653944) in adults with obesity disease, a condition in which a person has too much body fat, which can harm their health and increase the risk of other medical problems. Some participant

ClinicalTrials.gov NCT07794774 protocol and results modules

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT07794761

A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW). Overall status RECRUITING. Phases PHASE3. Lead sponsor Pfizer. Enrollment 180. Conditions Obesity. The purpose of this clinical study is to learn about safety and effects of berobenatide (PF-08653944) in adults with obesity disease, a condition where a person has too much body fat, which can harm their health and increase the risk of other medical problems. Some people in this

ClinicalTrials.gov NCT07794761 protocol and results modules

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT06973720

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight. Overall status COMPLETED. Phases PHASE2. Lead sponsor Pfizer. Enrollment 268. Conditions Obesity; Overweight or Obesity. This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo. Participants are eligible if they have overweight or obesity and do not have type 2 diabetes.

ClinicalTrials.gov NCT06973720 protocol and results modules

registry, as of 2026-08-28Stale

https://clinicaltrials.gov/study/NCT06712836

A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight. Overall status COMPLETED. Phases PHASE2. Lead sponsor Pfizer. Enrollment 239. Conditions Obesity; Overweight or Obesity. This study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks. If an individual is assigned to MET097 they will receive one of four deaths Part A: Placebo QW 0 nausea Part A: Placebo QW 13 vomiting Part A: Placebo QW 6 diarrhoea Part A: Placebo QW 5

ClinicalTrials.gov NCT06712836 protocol and results modules

Studies

VESPER-4

Registry NCT07311850

Phase Phase 3

Status Active, not recruiting

Enrollment 3578

Start 2025-12-19

Primary completion 2027-09-21

Study completion 2028-04-25

Catalyst Primary completion. 2027-09-21. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

MET097 Dose 1

Regimen once weekly

Weeks 84

Comparator placebo

Population Obesity and Overweight

MET097 Dose 2

Regimen once weekly

Weeks 84

Comparator placebo

Population Obesity and Overweight

MET097 Dose 3

Regimen once weekly

Weeks 84

Comparator placebo

Population Obesity and Overweight

Placebo

Regimen once weekly

Weeks 84

Population Obesity and Overweight

A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)

Registry NCT07915609

Phase Phase 3

Status Recruiting

Enrollment 756

Start 2026-10-26

Primary completion 2028-08-21

Study completion 2028-10-30

Catalyst Primary completion. 2028-08-21. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Placebo

Regimen once weekly

Weeks 52

Population Obesity; Overweight and/or Obesity; Knee Osteoarthritis; Diabetes Melliuts, Type 2

Arm 1: Berobenatide Once Weekly

Regimen once weekly

Weeks 52

Comparator placebo

Population Obesity; Overweight and/or Obesity; Knee Osteoarthritis; Diabetes Melliuts, Type 2

Arm 2: Berobenatide Once Weekly

Regimen once weekly

Weeks 52

Comparator placebo

Population Obesity; Overweight and/or Obesity; Knee Osteoarthritis; Diabetes Melliuts, Type 2

Arm 3: Berobenatide Once Weekly

Regimen once weekly

Weeks 52

Comparator placebo

Population Obesity; Overweight and/or Obesity; Knee Osteoarthritis; Diabetes Melliuts, Type 2

A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

Registry NCT07845500

Phase Phase 3

Status Recruiting

Enrollment 660

Start 2026-09-30

Primary completion 2028-02-16

Study completion 2028-02-16

Catalyst Primary completion. 2028-02-16. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Active Comparator

Regimen once monthly

Population Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity

Experimental

Regimen once monthly

Population Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity

A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

Registry NCT07919678

Phase Phase 3

Status Recruiting

Enrollment 656

Start 2026-10-26

Primary completion 2028-08-22

Study completion 2028-10-10

Catalyst Primary completion. 2028-08-22. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Placebo

Regimen once monthly

Weeks 52

Population Obesity; Overweight; Osteoarthritis of the Knee

Arm 1: Berobenatide Once Monthly

Regimen once monthly

Weeks 52

Comparator placebo

Population Obesity; Overweight; Osteoarthritis of the Knee

Arm 2: Berobenatide Once Monthly

Regimen once monthly

Weeks 52

Comparator placebo

Population Obesity; Overweight; Osteoarthritis of the Knee

Arm 3: Berobenatide Once Monthly

Regimen once monthly

Weeks 52

Comparator placebo

Population Obesity; Overweight; Osteoarthritis of the Knee

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity

Registry NCT07874633

Phase Phase 3

Status Recruiting

Enrollment 432

Start 2026-10-28

Primary completion 2028-06-06

Study completion 2028-08-15

Catalyst Primary completion. 2028-06-06. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Placebo

Regimen once monthly

Weeks 59

Population Obesity; Overweight

Treatment Arm 1

Regimen once monthly

Weeks 59

Comparator placebo

Population Obesity; Overweight

Treatment Arm 2

Regimen once monthly

Weeks 59

Comparator placebo

Population Obesity; Overweight

Treatment Arm 3

Regimen once monthly

Weeks 59

Comparator placebo

Population Obesity; Overweight

Treatment Arm 4

Regimen once monthly

Weeks 59

Comparator placebo

Population Obesity; Overweight

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

Registry NCT07792954

Phase Phase 3

Status Recruiting

Enrollment 300

Start 2026-09-24

Primary completion 2028-03-14

Study completion 2028-05-23

Catalyst Primary completion. 2028-03-14. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Berobenatide Medium Maintenance Dose

Regimen once weekly

Comparator placebo

Population Obesity; Overweight

Placebo Matched to Low-Dose Berobenatide

Regimen once weekly

Population Obesity; Overweight

Berobenatide Low Maintenance Dose

Regimen once weekly

Comparator placebo

Population Obesity; Overweight

Berobenatide High Maintenance Dose

Regimen once weekly

Comparator placebo

Population Obesity; Overweight

Placebo Matched to Medium-Dose Berobenatide

Regimen once weekly

Population Obesity; Overweight

Placebo Matched to High-Dose Berobenatide

Regimen once weekly

Population Obesity; Overweight

VESPER-OSA 2

Registry NCT07881757

Phase Phase 3

Status Recruiting

Enrollment 258

Start 2026-10-19

Primary completion 2028-06-01

Study completion 2028-07-20

Catalyst Primary completion. 2028-06-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Berobenatide

Regimen once monthly

Comparator placebo

Population Apnea; Sleep Disorders; Overweight and/or Obesity

Placebo

Regimen once monthly

Population Apnea; Sleep Disorders; Overweight and/or Obesity

A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (P

Registry NCT07823608

Phase Phase 3

Status Recruiting

Enrollment 258

Start 2026-09-17

Primary completion 2028-04-30

Study completion 2028-06-18

Catalyst Primary completion. 2028-04-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Treatment Arm

Regimen once monthly

Comparator placebo

Population Apnea; Sleep Disorders; Overweight and/or Obesity

Placebo

Regimen once monthly

Population Apnea; Sleep Disorders; Overweight and/or Obesity

A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)

Registry NCT07794774

Phase Phase 3

Status Recruiting

Enrollment 197

Start 2026-09-29

Primary completion 2029-02-21

Study completion 2029-02-21

Catalyst Primary completion. 2029-02-21. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Treatment Arm 1

Regimen once monthly

Comparator placebo

Population Obesity

Placebo

Regimen once monthly

Population Obesity

Treatment Arm 2

Regimen once monthly

Comparator placebo

Population Obesity

Treatment Arm 3

Regimen once monthly

Comparator placebo

Population Obesity

Treatment Arm 4

Regimen once monthly

Comparator placebo

Population Obesity

A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)

Registry NCT07794761

Phase Phase 3

Status Recruiting

Enrollment 180

Start 2026-10-02

Primary completion 2029-03-14

Study completion 2029-03-14

Catalyst Primary completion. 2029-03-14. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Treatment Arm 2

Regimen once weekly

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Population Obesity

Treatment Arm 3

Regimen once weekly

Comparator placebo

Population Obesity

Treatment Arm 1

Regimen once weekly

Comparator placebo

Population Obesity

VESPER-3

Registry NCT06973720

Phase Phase 2

Status Completed

Enrollment 268

Start 2025-04-07

Primary completion 2025-12-16

Study completion 2026-10-19

Catalyst Primary completion. 2025-12-16. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

MET097

Regimen once monthly

Weeks 12

Comparator placebo

Population Obesity; Overweight or Obesity

Placebo

Regimen once monthly

Weeks 12

Population Obesity; Overweight or Obesity

VESPER-1

Registry NCT06712836

Phase Phase 2

Status Completed

Enrollment 239

Start 2024-10-09

Primary completion 2025-07-03

Study completion 2026-04-30

Catalyst Primary completion. 2025-07-03. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

MET097 Active

Regimen once weekly

Weeks 28

Comparator placebo

Population Obesity; Overweight or Obesity

Placebo

Regimen once weekly

Weeks 28

Population Obesity; Overweight or Obesity

deaths

participants with nausea, 13 participantsStale

participants with vomiting, 6 participantsStale

participants with diarrhoea, 5 participantsStale